Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The Greater Manchester Cancer Alliance

Daiichi and ArQule pull late-stage study of lung cancer drug

Fails to reach primary endpoint of overall survival

Ariad’s lung cancer drug impresses at ESMO

Early stage trials demonstrate potential in hard-to-treat patients

- PMLiVE

AZ share buyback suspension prompts M&A speculation

Analysts query new CEO Pascal Soriot’s intention to preserve cash reserves

- PMLiVE

AZ launches science blog LabTalk

Hopes new blog will build relationships with potential collaborators

- PMLiVE

Boehringer cancer R&D programme bears first fruit

Submits afatinib in Europe to treat lung cancer

- PMLiVE

Merck withdraws EU filing for Erbitux in lung cancer

Follows request from EMA for more data

- PMLiVE

Lilly’s poor run continues as Alimta fails in lung cancer

Phase III trial comparing it to Roche's Avastin misses primary endpoint

- PMLiVE

AstraZeneca drops Palatin’s obesity drug after trial subject suffers allergic reaction

But collaboration with the US biotech remains in place

AstraZeneca and BGT shelve experimental sepsis drug

Decision follows CytoFab’s poor mid-stage clinical trial results

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links